SEARCH RESULTS

24 RESULTS

Paul Aisen on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT This is terribly disappointing; a major blow to the field. Aducanumab was the leading AD therapeutic program, and a source of hope for everyone. We now need to evaluate the trial data to learn all we can and determine the implications for the field. It is ...

Paul Aisen on There’s No Tomorrow for TOMMORROW

COMMENT It is always very disappointing when a major effort to test an intervention aiming to slow the AD process ends without evidence of efficacy. I am sure that a full analysis of the data collected will nonetheless advance the field; we always learn from ...

Current Filters

  • TYPE: Comment x
  • Commentator: Aisen, Paul x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE